LIFE earnings
Ethos Technologies Inc. (LIFE) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026AUSTIN, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it will release its financial results for the first quarter of 2026, which ended March 31, 2026, following the close of U.S. financial markets on Wednesday, May 6, 2026. The company's earnings press release will be made available on the Ethos Investor Relations website at investors.ethos.com. Ethos executives will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET the same day. The live webcast of the conference call can be found on the Ethos Investor Relatio
- Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsRecords full-year revenue of $387.6 million, growing 52% year-over-yearAchieves Net Income of $24.6 million and Adjusted EBITDA of $25.8 million in Q4, reflecting a 22% margin and a 23% Adjusted EBITDA marginDelivers third consecutive year of revenue growth greater than 50% AUSTIN, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ:LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. "We delivered a strong close to 2025 with 65% year-over-year revenue growth in Q4," said Peter Colis, CEO and Co-Founder of Ethos. "Our financial resul
- aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate UpdatePhase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged
- aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial ResultsSAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7
- aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial ResultsSAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051
- aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate UpdateFirst patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value driver efzofitimod program. Ended the third quarter 2022 with $79.6 million in cash, restricted cash, cash equivalents and investments. Company to host conference call and webcast today, November 10th, at 5:00 p.m. EST / 2:00 p.m. PST. SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quart
- aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial ResultsSAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report third quarter 2022 financial results and provide a corporate update after the market close on Thursday, November 10, 2022. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, November 10, 2022Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI4b50025644f64e129d555aeb8993aeb1Webca
- aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate UpdateFirst sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the second quarter 2022 with $89.3 million in cash, restricted cash, cash equivalents and investments. Company to host conference call and webcast today, May 15th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2022 results and provided a corporate update. "We are
- aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial ResultsSAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report second quarter 2022 financial results and provide a corporate update after the market close on Monday, August 15, 2022. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Monday, August 15, 2022Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI5d7604e9c0b54bbc88aaa9841cb67823Webcast Regi
- aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate UpdateCompany to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod in pulmonary sarcoidosis on track to initiate in the third quarter of 2022. FDA granted orphan drug designation for efzofitimod for the treatment of systemic sclerosis; company to explore potential expansion of clinical program in other ILD. Ended the first quarter 2022 with $98.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, May 9th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NA
- aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial ResultsSAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report first quarter 2022 financial results and provide a corporate update after the market close on Monday, May 9, 2022. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Monday, May 9th @ 5:00 p.m. EDT / 2:00 p.m. PDTDomestic: 844-358-9116International: 209-905-5951Conference ID: 9273437Webcast: http://investors.atyrpharma.com/events-and-webcasts About aTyr aTyr i
- aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate UpdateFDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarter of 2022. Company ended 2021 with $107.9 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced fourth quarter and full year 2021 results and provided a corporate update. "2021 was a milestone year for aTyr, w
- aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2021 Financial ResultsSAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update after the market close on Monday, March 14, 2022. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Monday, March 14th @ 5:00 p.m. EDT / 2:00 p.m. PDTDomestic: 844-358-9116International: 209-905-5951Conference ID: 3686825Webcast: http://investors.atyrpharma.com/events-and-webca
- aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial ResultsSAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2021 financial results and provide a corporate update after the market close on Wednesday, November 10, 2021. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Wednesday, November 10th @ 5:00 pm EST / 2:00 pm PSTDomestic: 844-358-9116International: 209-905-5951Conference ID: 9134928Webcast: http://investors.atyrpharma.com/events-and-webcasts
- aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary SarcoidosisTrial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the group able to taper completely off of steroids. Clinically meaningful improvements in forced vital capacity (FVC) of 3.3% and all sarcoidosis symptom measures, including shortness of breath, cough, and fatigue, observed in the 5.0 mg/kg treatment group. Management to host conference call and webcast today, September 13th at 8:30am ET/5:30am PT SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotherapeutics company engaged in the discovery and
- aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate UpdateData from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021. Company to host conference call and webcast today, August 10th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced second quarter 2021 results and provided a corporate update. "We recently completed the last subject visit in our Phase 1b/2a proof-of-concept study of our lead therapeutic candidate, ATYR1923, in pulmonary sarcoidosis, our initial interstitial lung disease (ILD) indi
- aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial ResultsSAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report second quarter 2021 financial results and provide a corporate update after the market close on Tuesday, August 10, 2021. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Tuesday, August 10th @ 5:00 pm EDT / 2:00 pm PDTDomestic: 844-358-9116International: 209-905-5951Conference ID: 4692110Webcast: http://investors.atyrpharma.com/events-and-webcasts About aTyr